Clinical trials: Neuroepithelial Tumor
Glioma, Immune Suppression
Immune and Inflammatory Indices in Peripheral Blood Predict Prognosis of Glioma and Correlate With Grades and Subtypes
Our study considered the relevant immune and inflammatory indices, such as immunoglobulin kappa light chain, TNF, and CD4+ Helper T lymphocyte% in a multi-institutional study with a large patient cohort (n=1282) from the east…
- Trial name
- NCT05635435
- Testing
- Detection of Immune and Inflammatory Indices in Peripheral Blood
- Where
- 3 sites in China
- Volunteers
- 1,282 people
- Sponsor
- Sun Yat-sen University
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Glioblastoma
Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247, Beijing YSCell Biotech Co., Ltd. [Abbreviated as YS])in Patients With Recurrent or Progressive Glioblastoma
This is a single-center, open-label, dose-escalation, multiple-dose investigator-initiated trial (IIT). The trial aims to evaluate the safety and tolerability of autologous dendritic cell injection sensitized with tumor…
- Trial name
- NCT07678138
- Testing
- Neoantigen DC Vaccine (YS247) for Glioblastoma
- Volunteers
- 9 people
- Sponsor
- Huanhu Hospital Affiliated to Tianjin Medical University
High Risk Neuroblastoma, Recurrent Neuroblastoma
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
This phase I trial is to find out the best dose, possible benefits and/or side effects of magrolimab in combination with dinutuximab in treating patients with neuroblastoma that has come back (relapsed) or does not respond to…
- Conditions
- High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma
- Trial name
- NCT04751383
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 11 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Glioma
Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors
Advances in medical care have significantly improved survival among children with cancer. In China, the 5-year survival rate has reached 71.9%.
- Conditions
- Cancer, Glioma, Leukemia (Both ALL and AML)
- Trial name
- SC-Het-GM-CCS (NCT07450872)
- Where
- China
- Volunteers
- 600 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Glioblastoma Multiforme
MRI Hypoxia Study for Glioblastoma Multiforme (GBM) Radiation Therapy
This study is designed to evaluate the role of Oxygen Enhanced (OE) Magnetic resonance imaging (MRI) and Blood Oxygenation Level Dependent (BOLD) MRI in detecting regions of hypoxic tumour and to evaluate their use as imaging…
- Trial name
- MANGO (NCT05500612)
- Where
- 2 sites in Australia
- Volunteers
- 20 people
- Sponsor
- University of Sydney
Pituitary Tumor, Meningioma
Long-Term Longitudinal QoL in Patients Undergoing EEA
This is a prospective longitudinal study to access postoperative 2-year quality of life in patients who undergo endonasal endoscopic approach surgeries of the skull base.
- Conditions
- Pituitary Tumor, Meningioma, Rathke Cleft Cysts, Chordoma
- Trial name
- NCT04087902
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Ohio State University
Glial Tumor
Sophrology Treatment for Patients With Glial Tumours Requiring Speech Therapy
Patients with brain tumours experience a loss of independence, which may occur suddenly or gradually. Communication with the patient may be rapidly impaired, due to impaired alertness, language and/or neurocognitive disorders.
- Trial name
- SOPHNEURO (NCT05189366)
- Testing
- Sophrology, Speech therapy
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Institut Cancerologie de l'Ouest
Glioma, Glioblastoma Multiforme
Study of DC Vaccination Against Glioblastoma
This is a Phase II study in a single center to determine the efficacy of autologous dendritic cells (DCs) loaded with autogeneic glioma stem-like cells (A2B5+) administered as a vaccination in adults with glioblastoma multiforme…
- Conditions
- Glioma, Glioblastoma Multiforme, Neoplasms
- Trial name
- NCT01567202
- Testing
- Surgery, Chemotherapy, Radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Huashan Hospital
Glioblastoma, Adult
Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)
Fluorescence guidance is a safe and efficient tool for glioblastomas resection. The most widely used technique is based on 5-aminolevulinic acid (5ala), which stains glioblastoma cells through a metabolic abnormality and thus…
- Trial name
- FLEGME (NCT03291977)
- Testing
- Fluorescéine Sodique Faure, White-light surgery
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Rennes University Hospital
Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2
Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study comparing the efficacy and safety of safusidenib versus placebo in participants with residual or recurrent Grade 2 glioma (oligodendroglioma or…
- Conditions
- Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2, Oligodendroglioma, Oligodendroglioma IDH-mutant and 1p/19q-codeleted
- Trial name
- NCT07712757
- Testing
- Safusidenib
- Volunteers
- 140 people
- Sponsor
- Nuvation Bio Inc.
Glioblastoma
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
This randomized phase II trial studies how well dose-escalated photon intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy works compared with standard-dose radiation therapy when given with temozolomide…
- Trial name
- NCT02179086
- Testing
- Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Temozolomide
- Where
- 237 sites in United States, Canada
- Volunteers
- 624 people
- Sponsor
- NRG Oncology
Neuroblastoma
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01493830
- Testing
- fluorescence in situ hybridization, gene expression analysis, microarray analysis
- Volunteers
- 5 people
- Sponsor
- Children's Oncology Group
Brain Tumors
Dose Response of Functionally Critical Brain Regions for Brain Radiotherapy
Normal tissue response is critical for brain radiotherapy, especially for dose escalation which carries with it an increased incidence of radiation-induced brain injury.
- Trial name
- NCT01212237
- Testing
- fMRI Evaluation
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Intracranial Tumors, Glioblastoma
A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy
This research study is studying the changes in primary and metastatic brain tumor inflammation using positron emission tomography (PET) imaging using a radioactive substance called [11C] PBR28a, which is also known as peripheral…
- Conditions
- Intracranial Tumors, Glioblastoma, Melanoma
- Trial name
- NCT02431572
- Testing
- PBR PET, Cancer Immunotherapy, Radiation and chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Anaplastic Astrocytoma, Central Nervous System Neoplasm
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
This phase II trial is studying how well giving radiation therapy together with temozolomide and lomustine works in treating young patients with newly diagnosed gliomas.
- Conditions
- Anaplastic Astrocytoma, Central Nervous System Neoplasm, Glioblastoma, Gliosarcoma
- Trial name
- NCT00100802
- Testing
- Laboratory Biomarker Analysis, Lomustine, Radiation Therapy
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Children's Oncology Group
Transcriptomics, Radiomics
Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data
This project intends to use multiple types of biological samples from glioma patients and mouse intracranial tumor models as research objects, and comprehensively apply a series of omics sequencing technologies and molecular…
- Conditions
- Transcriptomics, Radiomics, Glioma
- Trial name
- NCT04792437
- Testing
- surgery
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Yu Yao, MD
Glioma, Brain Neoplasms
Determination of Fraction Size Equivalent Dose (FED) Levels for Intracranial Conformal Avoidance Radiotherapy
The primary objective is to evaluate and quantify the reproducibility of functional magnetic resonance imaging (fMRI) maps of the eloquent brain areas corresponding to specific neurological functions based on activation maps…
- Trial name
- NCT00214175
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Wisconsin, Madison
Brain Tumors, Nervous System Tumors
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
RATIONALE: Armodafinil may help relieve fatigue and improve quality of life in patients with cancer receiving radiation therapy to the brain.
- Conditions
- Brain Tumors, Nervous System Tumors, Cognition Disorders, Fatigue
- Trial name
- NCT01032200
- Testing
- Armodafinil
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Wake Forest University Health Sciences
Recurrent Glioblastoma
Phase 2 Clinical Trial of KH617
To evaluate the efficacy and safety of KH617 for injection in combination with temozolomide versus investigator's choice therapy or KH617 monotherapy for recurrent glioblastoma
- Trial name
- NCT07138001
- Testing
- KH617+TMZ, KH617, TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16
- Volunteers
- 60 people
- Sponsor
- Sichuan Honghe Biotechnology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.